Clinical trials recruiting for Renal cell carcinoma
28
Recruiting trials
37
US states with sites
12
Countries
7%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Nivolumab | 4 |
| Pembrolizumab | 3 |
| Ipilimumab | 2 |
| A2B395 | 1 |
| AZD6750 | 1 |
| Alintegimod | 1 |
| Atezolizumab | 1 |
| Bevacizumab | 1 |
| Cancer Therapeutic Procedure | 1 |
| Carboplatin | 1 |
| Carboplatin (AUC 5) | 1 |
| Carboplatin AUC-6 | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 11 |
| Florida | 10 |
| Texas | 10 |
| New York | 6 |
| Ohio | 6 |
| Pennsylvania | 6 |
| Colorado | 5 |
| Arizona | 4 |
| Michigan | 4 |
| Missouri | 4 |
| Tennessee | 4 |
| Massachusetts | 3 |
Top cities
San Antonio, Texas 6Dallas, Texas 5Los Angeles, California 5Houston, Texas 4Nashville, Tennessee 4New York, New York 4St Louis, Missouri 4Boston, Massachusetts 3Cleveland, Ohio 3Grand Rapids, Michigan 3
Self-screener
Recruiting trials
- A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- A Multicenter Cancer Biospecimen Collection Study
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
- A Study of VET3-TGI in Patients With Solid Tumors
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
- Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
- DESTINY-PANTUMOUR04
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
- GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
- IDOV-Immune for Advanced Solid Tumors
- Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
- Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
- Retifanlimab and Ruxolitinib In Solid Malignancies
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
- The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Related conditions
Trials recruiting for Renal cell carcinoma often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Melanoma 487Breast cancer 2239Non-small cell lung cancer 507Hepatocellular carcinoma 51Colorectal cancer 1359Urothelial Carcinoma 29Triple-negative breast cancer 138Pancreatic cancer 870Cervical cancer 71
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Renal cell carcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.